RU2010101302A - Замещенные оксазолидиноны и их применение - Google Patents

Замещенные оксазолидиноны и их применение Download PDF

Info

Publication number: RU2010101302A
Authority: RU; Russia
Prior art keywords: alkyl; alkoxy; hydroxy; means hydrogen; group
Prior art date: 2007-06-20

Application number

RU2010101302/04A

Other languages

English (en)

Russian (ru)

Inventor

Сузанне РЕРИГ (DE)

Сузанне РЕРИГ

Михаэль ХЭРТЕР (DE)

Михаэль ХЭРТЕР

Марк Жан ГНОТ (DE)

Марк Жан ГНОТ

ДЕГЕНФЕЛЬД Жорж ФОН (DE)

ДЕГЕНФЕЛЬД Жорж ФОН

Эльке ДИТТРИХ-ВЕНГЕНРОТ (DE)

Эльке ДИТТРИХ-ВЕНГЕНРОТ

Аня БУХМЮЛЛЕР (DE)

Аня БУХМЮЛЛЕР

Свен АЛЛЕРХАЙЛИГЕН (DE)

Свен АЛЛЕРХАЙЛИГЕН

Элизабет ПЕРЦБОРН (DE)

Элизабет ПЕРЦБОРН

Кристоф ГЕРДЕС (DE)

Кристоф Гердес

Карл-Хайнц ШЛЕММЕР (DE)

Карл-Хайнц Шлеммер

Метин АКБАБА (DE)

Метин АКБАБА

Original Assignee

Байер Шеринг Фарма Акциенгезельшафт (DE)

Байер Шеринг Фарма Акциенгезельшафт

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-20

Filing date

2008-06-07

Publication date

2011-07-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39765012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2010101302(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-07 Application filed by Байер Шеринг Фарма Акциенгезельшафт (DE), Байер Шеринг Фарма Акциенгезельшафт filed Critical Байер Шеринг Фарма Акциенгезельшафт (DE)

2011-07-27 Publication of RU2010101302A publication Critical patent/RU2010101302A/ru

Links

IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 claims abstract 35
239000001257 hydrogen Substances 0.000 claims abstract 35
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 32
150000002431 hydrogen Chemical group 0.000 claims abstract 28
150000001875 compounds Chemical class 0.000 claims abstract 23
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 12
125000000217 alkyl group Chemical group 0.000 claims abstract 10
125000003545 alkoxy group Chemical group 0.000 claims abstract 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 6
125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 5
150000003839 salts Chemical class 0.000 claims 10
239000012453 solvate Substances 0.000 claims 10
239000003814 drug Substances 0.000 claims 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
229910052801 chlorine Inorganic materials 0.000 claims 6
239000000460 chlorine Substances 0.000 claims 6
230000006806 disease prevention Effects 0.000 claims 6
238000004519 manufacturing process Methods 0.000 claims 5
208000005189 Embolism Diseases 0.000 claims 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
208000001435 Thromboembolism Diseases 0.000 claims 4
229940079593 drug Drugs 0.000 claims 4
229910052731 fluorine Inorganic materials 0.000 claims 4
239000011737 fluorine Substances 0.000 claims 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
206010053159 Organ failure Diseases 0.000 claims 3
238000000034 method Methods 0.000 claims 3
-1 methoxy, ethoxy Chemical group 0.000 claims 3
230000002265 prevention Effects 0.000 claims 3
206010069351 acute lung injury Diseases 0.000 claims 2
239000003146 anticoagulant agent Substances 0.000 claims 2
229940127219 anticoagulant drug Drugs 0.000 claims 2
230000023555 blood coagulation Effects 0.000 claims 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
238000000338 in vitro Methods 0.000 claims 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
241001465754 Metazoa Species 0.000 claims 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
206010040047 Sepsis Diseases 0.000 claims 1
206010040070 Septic Shock Diseases 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
229910052794 bromium Inorganic materials 0.000 claims 1
230000015271 coagulation Effects 0.000 claims 1
238000005345 coagulation Methods 0.000 claims 1
125000004093 cyano group Chemical group *C#N 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical group 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 claims 1
230000003000 nontoxic effect Effects 0.000 claims 1
230000004768 organ dysfunction Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
208000002815 pulmonary hypertension Diseases 0.000 claims 1
230000036303 septic shock Effects 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
230000009885 systemic effect Effects 0.000 claims 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 11
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 8
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
0 CC(CCCN1*)C1=O Chemical compound CC(CCCN1*)C1=O 0.000 description 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

RU2010101302/04A 2007-06-20 2008-06-07 Замещенные оксазолидиноны и их применение RU2010101302A (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102007028320A DE102007028320A1 (de)	2007-06-20	2007-06-20	Substituierte Oxazolidinone und ihre Verwendung
DE102007028320.4		2007-06-20

Publications (1)

Publication Number	Publication Date
RU2010101302A true RU2010101302A (ru)	2011-07-27

Family

ID=39765012

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2010101302/04A RU2010101302A (ru)	2007-06-20	2008-06-07	Замещенные оксазолидиноны и их применение

Country Status (26)

Country	Link
US (1)	US20100184767A1 (de)
EP (1)	EP2167495A1 (de)
JP (1)	JP2010530385A (de)
KR (1)	KR20100029213A (de)
CN (1)	CN101772496A (de)
AR (1)	AR067058A1 (de)
AU (1)	AU2008266527A1 (de)
BR (1)	BRPI0813263A2 (de)
CA (1)	CA2692172A1 (de)
CL (1)	CL2008001703A1 (de)
CO (1)	CO6251282A2 (de)
CR (1)	CR11169A (de)
DE (1)	DE102007028320A1 (de)
DO (1)	DOP2009000287A (de)
EC (1)	ECSP099806A (de)
GT (1)	GT200900318A (de)
IL (1)	IL202073A0 (de)
MA (1)	MA31570B1 (de)
MX (1)	MX2009013710A (de)
PA (1)	PA8784101A1 (de)
PE (1)	PE20090333A1 (de)
RU (1)	RU2010101302A (de)
TN (1)	TN2009000484A1 (de)
TW (1)	TW200914447A (de)
UY (1)	UY31136A1 (de)
WO (1)	WO2008155034A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102464658B (zh) *	2010-11-03	2014-04-16	天津药物研究院	噁唑烷酮衍生物及其制备方法和用途
CN103619883A (zh)	2011-01-19	2014-03-05	拜耳知识产权有限责任公司	凝血因子抑制剂的结合蛋白
CZ2012114A3 (cs) *	2012-02-17	2013-02-20	Zentiva, K.S.	Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
EP2838897A1 (de) *	2012-04-16	2015-02-25	Ranbaxy Laboratories Limited	Verfahren zur herstellung von rivaroxaban und zwischenprodukten davon
BR112014030284B1 (pt)	2012-07-18	2021-11-30	Sunshine Lake Pharma Co., Ltd	Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CN102746250B (zh) *	2012-07-24	2016-03-02	瑞阳制药有限公司	N-[[3-(3-氟-4-吗啉基-4-基-苯基)-2-恶唑酮基-5-基]甲基]-2-甲氨基-苯甲酰胺的制备方法
CN103833724A (zh) *	2012-11-20	2014-06-04	上海医药工业研究院	一种5-氯噻吩-2-甲酰氯的制备方法
CN103242307B (zh) *	2013-05-17	2015-08-12	天津药物研究院有限公司	一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CN104163819A (zh) *	2013-05-17	2014-11-26	天津药物研究院	一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN105473558B (zh)	2013-06-20	2019-04-19	拜耳作物科学股份公司	作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
ES2712211T3 (es)	2013-06-20	2019-05-09	Bayer Cropscience Ag	Derivados de arilsulfuro y arilsulfóxido acaricidas e insecticidas
BR112016000241B1 (pt)	2013-07-08	2021-06-22	Bayer Cropscience Aktiengesellschaft	Compostos pesticidas derivados de sulfeto de arila e sulfóxido de arila, formulação, seus usos, método para controle de pragas e método de proteção de semente ou planta
CN104016975B (zh) *	2014-06-27	2017-01-11	深圳翰宇药业股份有限公司	利伐沙班的制备方法
CN104447729A (zh) *	2014-12-05	2015-03-25	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
EP3078378B1 (de)	2015-04-08	2020-06-24	Vaiomer	Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie
JP7205529B2 (ja) *	2018-02-26	2023-01-17	住友化学株式会社	オキサゾリジノン化合物の製造方法
KR102422628B1 (ko)	2020-03-20	2022-07-18	마인도어 사회적협동조합	보드 게임 도구
CN116731093B (zh) *	2023-05-17	2026-03-27	台州市生物医化产业研究院有限公司	从三叶青中提取山奈酚-3-o-芸香糖苷的方法及山奈酚-3-o-芸香糖苷的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
US4444784A (en)	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
DK149080C (da)	1980-06-06	1986-07-28	Sankyo Co	Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de)	1992-10-23	1994-04-28	Bayer Ag	Trisubstituierte Biphenyle
DE19642255A1 (de)	1996-10-14	1998-04-16	Bayer Ag	Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
US6166027A (en)	1996-10-14	2000-12-26	Bayer Aktiengesellschaft	Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases
DE19649460A1 (de)	1996-11-26	1998-05-28	Bayer Ag	Neue substituierte Pyrazolderivate
DE19834045A1 (de)	1998-07-29	2000-02-03	Bayer Ag	(4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19846514A1 (de)	1998-10-09	2000-04-20	Bayer Ag	Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de)	1999-05-04	2000-11-09	Bayer Ag	Substituiertes Pyrazolderivat
DE19942809A1 (de)	1999-09-08	2001-03-15	Bayer Ag	Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de)	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB0405272D0 (en)	2004-03-09	2004-04-21	Trigen Ltd	Compounds
DE102005047558A1 (de) *	2005-10-04	2008-02-07	Bayer Healthcare Ag	Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050377A1 (de)	2005-10-21	2007-04-26	Bayer Healthcare Ag	Heterocyclische Verbindungen und ihre Verwendung
DE102005050498A1 (de)	2005-10-21	2007-06-06	Bayer Healthcare Aktiengesellschaft	Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050497A1 (de)	2005-10-21	2007-04-26	Bayer Healthcare Ag	Difluorphenol-Derivate und ihre Verwendung
DE102005050375A1 (de)	2005-10-21	2007-04-26	Bayer Healthcare Ag	Tetrazol-Derivate und ihre Verwendung
DE102005050376A1 (de)	2005-10-21	2007-05-31	Bayer Healthcare Ag	Dicarbonsäure-Derivate und ihre Verwendung
DE102007028406A1 (de) *	2007-06-20	2008-12-24	Bayer Healthcare Ag	Substituierte Oxazolidinone und ihre Verwendung
DE102007032345A1 (de) *	2007-07-11	2009-01-15	Bayer Healthcare Ag	Aminoacyl-Prodrugs
DE102007032347A1 (de) *	2007-07-11	2009-01-15	Bayer Healthcare Ag	Aminoacyl-Prodrugs

2007
- 2007-06-20 DE DE102007028320A patent/DE102007028320A1/de not_active Withdrawn
2008
- 2008-06-07 CA CA002692172A patent/CA2692172A1/en not_active Abandoned
- 2008-06-07 KR KR1020097026531A patent/KR20100029213A/ko not_active Withdrawn
- 2008-06-07 BR BRPI0813263-1A2A patent/BRPI0813263A2/pt not_active Application Discontinuation
- 2008-06-07 CN CN200880020715A patent/CN101772496A/zh active Pending
- 2008-06-07 JP JP2010512561A patent/JP2010530385A/ja active Pending
- 2008-06-07 AU AU2008266527A patent/AU2008266527A1/en not_active Abandoned
- 2008-06-07 MX MX2009013710A patent/MX2009013710A/es not_active Application Discontinuation
- 2008-06-07 US US12/665,727 patent/US20100184767A1/en not_active Abandoned
- 2008-06-07 WO PCT/EP2008/004564 patent/WO2008155034A1/de not_active Ceased
- 2008-06-07 EP EP08759100A patent/EP2167495A1/de not_active Withdrawn
- 2008-06-07 RU RU2010101302/04A patent/RU2010101302A/ru not_active Application Discontinuation
- 2008-06-10 CL CL2008001703A patent/CL2008001703A1/es unknown
- 2008-06-10 PA PA20088784101A patent/PA8784101A1/es unknown
- 2008-06-10 UY UY31136A patent/UY31136A1/es not_active Application Discontinuation
- 2008-06-11 PE PE2008000991A patent/PE20090333A1/es not_active Application Discontinuation
- 2008-06-19 AR ARP080102608A patent/AR067058A1/es unknown
- 2008-06-19 TW TW097122782A patent/TW200914447A/zh unknown
2009
- 2009-11-12 IL IL202073A patent/IL202073A0/en unknown
- 2009-11-18 TN TNP2009000484A patent/TN2009000484A1/fr unknown
- 2009-12-15 EC EC2009009806A patent/ECSP099806A/es unknown
- 2009-12-15 GT GT200900318A patent/GT200900318A/es unknown
- 2009-12-15 CR CR11169A patent/CR11169A/es not_active Application Discontinuation
- 2009-12-16 DO DO2009000287A patent/DOP2009000287A/es unknown
- 2009-12-17 CO CO09144718A patent/CO6251282A2/es not_active Application Discontinuation
2010
- 2010-01-19 MA MA32537A patent/MA31570B1/fr unknown

Also Published As

Publication number	Publication date
UY31136A1 (es)	2009-01-30
AU2008266527A1 (en)	2008-12-24
EP2167495A1 (de)	2010-03-31
MA31570B1 (fr)	2010-08-02
CN101772496A (zh)	2010-07-07
MX2009013710A (es)	2010-02-01
CR11169A (es)	2010-07-01
KR20100029213A (ko)	2010-03-16
TN2009000484A1 (en)	2011-03-31
IL202073A0 (en)	2010-06-16
US20100184767A1 (en)	2010-07-22
TW200914447A (en)	2009-04-01
PE20090333A1 (es)	2009-04-15
PA8784101A1 (es)	2009-02-09
GT200900318A (es)	2010-10-04
ECSP099806A (es)	2010-01-29
AR067058A1 (es)	2009-09-30
JP2010530385A (ja)	2010-09-09
BRPI0813263A2 (pt)	2014-12-30
WO2008155034A1 (de)	2008-12-24
DOP2009000287A (es)	2010-01-31
CO6251282A2 (es)	2011-02-21
DE102007028320A1 (de)	2008-12-24
CA2692172A1 (en)	2008-12-24
CL2008001703A1 (es)	2008-12-26

Legal Events

Date	Code	Title	Description
2011-08-27	FA93	Acknowledgement of application withdrawn (no request for examination)	Effective date: 20110719

Publication	Publication Date	Title
RU2010101302A (ru)	2011-07-27	Замещенные оксазолидиноны и их применение
RU2436780C2 (ru)	2011-12-20	Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
JP2014526500A5 (de)	2014-12-11
JP2005536475A5 (de)	2010-04-30
RU2487124C2 (ru)	2013-07-10	Новое амидное производное и его использование в качестве лекарственного средства
RU2006133898A (ru)	2008-03-27	Производные бензимидазола и его применение
RU2008116834A (ru)	2009-11-10	Новая полиморфная форма и аморфная форма 5-хлор-n-(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида
RU2010101307A (ru)	2011-07-27	Замещенные (оксазолидинон-5ил-метил)-2-тиофен-карбоксамиды и их применение в области свертывания крови
RU2009123525A (ru)	2010-12-27	ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
JP2007512299A5 (de)	2007-12-06
EA200600928A1 (ru)	2007-10-26	Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
PE20091339A1 (es)	2009-09-26	Derivados de oxadiazol con actividad sobre receptores s1p1
JP2011521911A5 (de)	2012-06-07
RU2009109159A (ru)	2010-09-27	Трансдермальное применение триазинов для борьбы с инфекциями кокцидий
PE20080360A1 (es)	2008-05-22	Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
JP2012510957A5 (de)	2012-12-27
RU2009119421A (ru)	2011-04-27	Производные 2-фенил-6-аминокарбонилпиримидина и их применение в качестве антагонистов тромбоцитарного рецептора адф (p2y12 рецептора)
RU2017118369A (ru)	2018-12-04	Соединения для применения в дегельминтизации
RU2009102270A (ru)	2010-08-10	Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
RU2019111421A (ru)	2020-11-06	Способы лечения острого повреждения почек
AR048808A1 (es)	2006-05-31	Pirrolocarbazoles fusionados
RU2009127852A (ru)	2011-01-27	Производные 4-(1-аминоэтил)циклогексиламина
JP2009501745A5 (de)	2009-09-10
RU2012114718A (ru)	2013-11-10	Пиридиновые соединения конденсированного кольца как подтип-селективные модуляторы рецепторов сфингозин-1-фосфата-2 (s1p2)
EA019037B1 (ru)	2013-12-30	5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1